American Conference Institute will be holding their 8th annual "Paragraph IV Disputes" conference on April 28-29 in New York. Highlights of the conference include a district court judges panel, a magistrate judges panel, and an FTC keynote address. Here is the complete agenda:
- On the 30th Anniversary of the Drug Price Competition and Patent Term Restoration Act: Understanding Hatch-Waxman's Transformative Impact on the Pharmaceutical Industry
- Assessing Pharmaceutical Patent Sustainability and Vulnerability: Strategies and Considerations for Brand Names and Generics in Anticipating, Identifying and Determining Which Patents Will be Ripe for Challenges of Invalidity and Non-Infringement
- Use of IPR and Other PTO Proceedings in a Paragraph IV Challenge: Strategies for Brand Names and Generics in Navigating PTO Proceedings in ANDA Litigation
- The Gauntlet Rethrown: The Paragraph IV Certification and Notice Letter
- Of Prior Art and Double Patenting: Exploring the Dichotomy Between the Federal Circuit and PTO on Obviousness Findings and Potential Impact of the Goodlatte Bill on Obviousness-Type Double Patenting
- Let the Games Begin: Advanced Strategies for Drafting and Perfecting Pleadings and Effectively Using Dispositive Motions in Paragraph IV Disputes
- Working With Local Counsel and Within Local Rules: Magistrate and Local Counsel Roundtable
- A View From the Bench: District Court Judges Panel
- Claim Construction and Markman Hearings: Standards, Jurisprudential Splits and Strategies for Paragraph IV Litigation
- FTC Keynote: Reverse Payment Settlements and Other Antitrust Concerns Impacting Paragraph IV Litigation in the Wake of Actavis
- Perils of the Safe Harbor: Understanding How the Resetting of the Boundaries of 271(e)(1) in the Aftermath of Classen and Momenta is Impacting Paragraph IV Litigation Strategies
- In the Limelight: Strategies and Theories of Inducement, Contributory, and Divided Infringement in Paragraph IV Litigation Concerning Method of Treatment Patents
- Assessing GDUFA Implementation and Additional Regulatory Developments of FDA Which Impact Paragraph IV Litigation
- Looking Beyond 180 Days: New Exclusivity Challenges for Brand Names and Generics and Related Implications for Paragraph IV Challenges
- A Pros and Cons Analysis of Launching At Risk and Survey of New Developments in Seeking Injunctive Relief and Damages
- Ethical Considerations for Paragraph IV Matters Before the PTO and District Courts: Inequitable Conduct and More
In addition to the main conference, ACI is offering a post-conference workshop on pharmaceutical patent settlements.
Orange Book Blog readers can receive discounted registration with code OBB200. For more information or to register, please visit the conference website.
Comments